Analysis and research on the published patents of novel coronavirus related technology / 中华医学科研管理杂志

ABSTRACT

Objective:By retrieving published patents on novel coronavirus related technologies, we analyzed the differences in patent applicants, target areas, patent quality, etc. in different countries and regions, and learned from the patent layout of relevant key innovation entities in countries and regions with relatively mature patent systems, such as Europe and the United States, to provide a reference for the subsequent writing and layout of related Chinese patents.Methods:" Novel coronavirus pneumonia, nCov pneumonia, novel coronavirus, nCov, COVID-19, 2019-nCoV, SARS-CoV-2" were searched as key words in the PatSnap Patent Database, with a limitation of public date before September 30, 2020. Based on the bibliometric method, this study analyzed applicants, regional distribution, patent quality, patent subject, etc.Results:4 541 patents on novel coronavirus related technology were obtained through search and filtering, whose applicants are mainly from China, which is also the major, region of applications. However, in an analysis of patent quality regarding novel coronavirus related technologies, the number of claims of US patent applications reached 44.48, and the number of patents in the same family reached 5.21, while in China, the numbers were just 9.27 (claims) and 1.45 (patents of the same family).Conclusions:China outperformed other countries in terms of the number of patent applications for novel coronavirus related technologies, but fell rather far behind the US in terms of patent quality and layout. Therefore, it is necessary to introduce and train professional patent management talents, improve the patent management system, raise awareness of patent legal protection, write high-quality legal documents, attach importance to the global market of patent technology, and strengthen the internationalization of patent layout, further promote industry-university-research cooperation, strengthen exchanges and cooperation among research institutions, pharmaceutical enterprises, hospitals and other institutions, pay attention to the combination of scientific research and clinical, prevention and control practices, and promote the healthy development of coronavirus research.